Sign inJoin waitlistJoin the waitlist

Naoyuki Saito

Assistant Professor of Clinical Radiation Oncology · Indiana University School of Medicine

Credentials: · · · · ·

History

Indiana University School of Medicine
Present

University of Michigan
2001–2005
Preliminary or Transitional Year
2000–2001
Perelman School of Medicine at the University of Pennsylvania
1996–2000

Research

Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization
Analytical Biochemistry · 2004 · 476 citations
Identification and characterization of two novel staphylococcal enterotoxins, types S and T
Infection and Immunity · 2008 · 136 citations
Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis…
Journal of Medicinal Chemistry · 2008 · 71 citations

Aaron Wolfson
3 papers
David Kirsch
3 papers
Dian Wang
3 papers
Ivy Petersen
3 papers
Michael Haddock
3 papers
SC
Steven Century
3 papers
Thomas Delaney
3 papers
Ying Hitchcock
3 papers
AZ
Andrew Zelenetz
2 papers
Ann LaCasce
2 papers
Bhagirathbhai Dholaria
2 papers
Boyu Hu
2 papers

Clinical trials

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Principal investigator · Withdrawn · Phase 1, Phase 2
Naoyuki G. Saito, M.D., Ph.D.
2023–2029
Prospective Validation of a Points Score System Predicting 30-day Survival
Principal investigator · Recruiting
Indiana University
2022–2028
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
Principal investigator · Terminated · Phase 1
Naoyuki G. Saito, M.D., Ph.D.
2018–2021
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Site PI · Recruiting · Phase 3
NRG Oncology
2021–2041